Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;7(6):e39110.
doi: 10.1371/journal.pone.0039110. Epub 2012 Jun 18.

Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease risk in women with high levels of HDL cholesterol and C-reactive protein

Affiliations

Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease risk in women with high levels of HDL cholesterol and C-reactive protein

James P Corsetti et al. PLoS One. 2012.

Abstract

Background: In a previous report by our group, high levels of apolipoprotein E (apoE) were demonstrated to be associated with risk of incident cardiovascular disease in women with high levels of C-reactive protein (CRP) in the setting of both low (designated as HR1 subjects) and high (designated as HR2 subjects) levels of high-density lipoprotein cholesterol (HDL-C). To assess whether apolipoprotein A-II (apoA-II) plays a role in apoE-associated risk in the two female groups.

Methodology/principal: Outcome event mapping, a graphical data exploratory tool; Cox proportional hazards multivariable regression; and curve-fitting modeling were used to examine apoA-II influence on apoE-associated risk focusing on HDL particles with apolipoprotein A-I (apoA-I) without apoA-II (LpA-I) and HDL particles with both apoA-I and apoA-II (LpA-I:A-II). Results of outcome mappings as a function of apoE levels and the ratio of apoA-II to apoA-I revealed within each of the two populations, a high-risk subgroup characterized in each situation by high levels of apoE and additionally: in HR1, by a low value of the apoA-II/apoA-I ratio; and in HR2, by a moderate value of the apoA-II/apoA-I ratio. Furthermore, derived estimates of LpA-I and LpA-I:A-II levels revealed for high-risk versus remaining subjects: in HR1, higher levels of LpA-I and lower levels of LpA-I:A-II; and in HR2 the reverse, lower levels of LpA-I and higher levels of LpA-I:A-II. Results of multivariable risk modeling as a function of LpA-I and LpA-I:A-II (dichotomized as highest quartile versus combined three lower quartiles) revealed association of risk only for high levels of LpA-I:A-II in the HR2 subgroup (hazard ratio 5.31, 95% CI 1.12-25.17, p = 0.036). Furthermore, high LpA-I:A-II levels interacted with high apoE levels in establishing subgroup risk.

Conclusions/significance: We conclude that apoA-II plays a significant role in apoE-associated risk of incident CVD in women with high levels of HDL-C and CRP.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Flow diagram of study design.
Figure 2
Figure 2. Outcome event map as a function of apoA-II/apoA-I ratio and apoE ranks in the total study population of women and men with iso-contour line of risk at 5.3% superimposed.
Figure 3
Figure 3. Outcome event maps as a function of apoA-II/apoA-I ratio and apoE ranks in women for: A. the background subgroup (BG); B. the low HDL-C/high CRP subgroup (HR1) with iso-contour line of risk at 5.3% superimposed; and C. the high HDL-C/high CRP subgroup (HR2) with iso-contour line of risk at 5.3% superimposed.
Figure 4
Figure 4. Outcome event maps as a function of apoA-II/apoA-I ratio and apoE ranks in men for: A. the background subgroup (BG); B. the low HDL-C/high CRP subgroup (HR1); and C. the high HDL-C/high CRP subgroup (HR2).
Figure 5
Figure 5. Kaplan-Meier plots for base subjects (heavy solid line) and peak subjects (light solid line) for: A. the low female HDL-C/high CRP subgroup (HR1) (p<0.0001, log-rank); and B. the female high HDL-C/high CRP subgroup (HR2) (p<0.0001, log-rank).
Figure 6
Figure 6. Kaplan-Meier curves in the female high-HDL-C/high CRP subgroup (HR2) as a function of combinations of dichotomized LpA-I:A-II and apoE levels as follows: light solid line - low LpA-I:A-II and low apoE, short dashes - low LpA-I:A-II and high apoE, long dashes - high LpA-I:A-II and low apoE, and heavy solid line - high LpA-I:A-II and high apoE.

References

    1. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol. 2008;23:370–378. - PubMed
    1. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels. J Am Coll Cardiol. 2008;51:2199–2211. - PMC - PubMed
    1. Sviridov D, Mukhamedova N, Remaley AT, Chin-Dusting J, Nestel P. Antiatherogenic functionality of high density lipoprotein: how much versus how good. J Atheroscler Thromb. 2008;15:52–62. - PubMed
    1. Ragbir S, Farmer JA. Dysfunctional high-density lipoprotein and atherosclerosis Curr Atheroscler Rep. 2010;12:343–348. - PubMed
    1. Shao B, Oda M, Oram JF, Heinecke JW. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol. 2010;23:447–454. - PMC - PubMed

Publication types